KarinCA's  Instablog

Send Message
I'm an independent writer/trader/investor whose primary interests are in the stem cell and biotech arena. My secondary interest is in oil/energy speculation. I do venture elsewhere at times. There’s an option to follow me at the top of any article I write. Click it and you’ll also see an option... More
  • Cellceutix Drug Kevetrin Achieves In-Vivo Tumor Shrinkage In Renal Cancer 0 comments
    Jan 24, 2013 2:33 AM | about stocks: CTIX

    Cellceutix Corp (OTCPK:CTIX) is based in Beverly, Massachusetts and is a clinical stage biotech company. Results are in from in vivo studies using Kevetrin at Beth Israel Deaconess Medical Center (BIDMC), which is a teaching hospital of Harvard Medical School.

    Kevetrin is the flagship drug in the Cellceutix pipeline.

    BIDMC combined Kevetrin™ with sunitinib on cell line 786, which is a drug-resistant renal cancer. This drug combination was the first time actual tumor shrinkage was seen in this line.

    This is extremely good news since renal cancer is very difficult to treat.

    Disclosure: I am long OTCPK:CTIX.

    Stocks: CTIX
Back To KarinCA's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


  • $CTIX - Releases Data Used in Receiving FDA Orphan Drug Designation of Kevetrin for Pancreatic Cancer https://shar.es/1huZ43 via @sharethis
    Jan 22, 2016
  • $CTIX - first new class of antibiotic to enter a Phase 3 clinical trial for ABSSSI in more than 2 decades. http://yhoo.it/1Q8tSpk
    Jan 14, 2016
  • $CTIX - My visit to Cellceutix, the biotech that a short seller recently called a sham http://bit.ly/1IR4I70
    Aug 14, 2015
More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.